Gene · 3785
KCNQ2: potassium voltage-gated channel subfamily Q member 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNQ2: potassium voltage-gated channel subfamily Q member 2. Genes, record 3785. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3785
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O43526 | Potassium voltage-gated channel subfamily KQT member 2 | 872 | 39 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026219910 A1 | 2026-10-22 | 13 | O43526 | Espacenet |
| JP 2026094314 A | 2026-06-09 | 105 | O43526 | Espacenet |
| JP 2026021360 A | 2026-02-10 | 133 | O43526 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58733 | O43526 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7660 | O43526 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2260 | O43526 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2260 | O43526 | Espacenet |
| WO 2025133292 A1 | 2025-06-26 | 1 | O43526 | Espacenet |
| EP 4574152 A1 | 2025-06-25 | 1 | O43526 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7660 | O43526 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| EZOGABINE | CHEMBL41355 | KCNQ (Kv7) potassium channel opener | OPENER | ChEMBL |
| FLINDOKALNER | CHEMBL266510 | Voltage-gated potassium channel subunit Kv7.2 activator | ACTIVATOR | ChEMBL |
| FLINDOKALNER | CHEMBL266510 | Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3) activator | ACTIVATOR | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
Trials96
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsNIH grants1,261
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNQ2 papers | Newest fiscal year |
|---|---|---|---|
| R01HL122010 | Decrypting Variants of Uncertain Significance in Long-QT Syndrome | 8 | 2025 |
| R01HL137094 | Role of KCNQ2 Channels in Control of Breathing | 8 | 2025 |
| R01NS107671 | Therapeutic small molecule modulation of Kv channels | 8 | 2025 |
| R35GM130377 | Ion Channel Transporter Interactions | 8 | 2025 |
| U24NS120854 | ClinGen Expert Curation Panel for the Epilepsies | 8 | 2025 |
| R01NS029709 | Excitability and Plasticity of Developing Epileptic Brain | 7 | 2025 |
| T32HL007446 | Pathobiology of Occlusive Vascular Disease | 7 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 6 | 2025 |
| P50HD105351 | Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center | 6 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
1 to 10 of 1,261Source NIH's project files
See all 1,261 nih grantsPapers2,279
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a Ste20-like kinase-dependent signaling network orchestrating cytoskeletal and synaptic development of cortical neurons. | Cell Commun Signal | 2026 | 42827256 | PubTator, text mining | PubMed |
| Loose-patch recordings reveal differential Kv7-dependent effects on spontaneous excitatory activity in control and epileptic CA1. | Front Neurol | 2026 | 42798466 | PubTator, text mining | PubMed |
| Kv7 channels as pharmacological targets for central nervous system diseases. | Pharmacol Rev | 2026 | 42772203 | PubTator, text mining | PubMed |
| [Effectiveness and tolerability of ketogenic diet therapy in children with genetic developmental and epileptic encephalopathy onset within 2 years of age]. | Zhonghua Er Ke Za Zhi | 2026 | 42742013 | PubTator, text mining | PubMed |
| Discovery of Novel Bicyclic Pyrazole Amides as Potent Neuronal KV7 Potassium Channel Openers with Strong Preclinical Antiseizure Activity. | ACS Med Chem Lett | 2026 | 42741311 | PubTator, text mining | PubMed |
| [Electroclinical recognition of SCN2A, SCN8A, KCNQ2, and KCNQ3 pathogenic variants]. | Medicina (B Aires) | 2026 | 42659555 | PubTator, text mining | PubMed |
Targeted Sequencing and Haplotype Analysis of Voltage-Gated Potassium Channel Genes Reveal a Potential Association of KCNV2 Haplotypes with Antiseizure Medication Response in Turkish Patients with Epilepsy. | Pharmaceuticals (Basel) | 2026 | 42653690 | PubTator, text mining | PubMed |
| Genomic Sequencing in Neonatal Encephalopathy and Suspected Hypoxic-Ischaemic Encephalopathy: A Systematic Review. | Genes (Basel) | 2026 | 42650055 | PubTator, text mining | PubMed |
| Molecular Basis for Activation to Inhibition Switching in Kv7.2 Channel Modulators. | Angew Chem Int Ed Engl | 2026 | 42631357 | PubTator, text mining | PubMed |
| Development of a human iPSC and patient phenotyping resource for preclinical investigations of neurodevelopmental disorders. | Stem Cell Res | 2026 | 42612424 | PubTator, text mining | PubMed |
1 to 10 of 2,279
See all 2,279 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3785
GET https://conductscience.org/api/genes/v1/3785/patents?page=2